Mustafa Özdoğan, MD· @ozdogan_md · X·· 1 day agoScore70
Body
VOLGA (LBA2, #ESMO26): cisplatin-ineligible/refusing MIBC — neoadjuvant enfortumab vedotin + peri-op durvalumab vs control.
Circulating figures (EV+durva arm): 2-yr EFS 64% vs 45% (HR 0.51); 2-yr OS 78% vs 69% (HR 0.58); pCR ~45% vs ~10%.
Tremelimumab arm: EFS HR ~0.61, OS NS at interim. Absolute rates unverified — confirm at PS I (Powles).
@tompowles1
143 views · 2 likes · 1 repost · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: Mustafa Özdoğan, MD · x.com